VeriSee DR
AI-assisted solutions for Diabetic Retinopathy (DR) identification
No ophthalmologist required
Can be expanded for use in community care
Quick screening for
high-risk cases
Helps ensure timely treatment
Integration with
medical record systems
Cross-disciplinary use
Improving the diagnosis and tracking process for DR
VeriSee DR is an AI diagnostic aid that has been trained using DR diagnosis experience from multiple ophthalmologists and uses AI deep learning techniques to produce diagnosis results similar to that of professional physicians. Acer Healthcare Inc. uses hardware integration to construct an edge computing device that can be used without a network connection.
AI-based Diagnosis Software for Diabetic Retinopathy
by Dr. Hsieh, Yi-Ting
Diabetic Retinopathy, DR
Normal Eye
Eye with Retinopathy
Healthy blood vessel
Tiny blood vessels
leak fluid into the retina
Diabetic Retinopathy (DR) can cause blindness
If diabetic patients fail to control their blood glucose levels and seek continuous medical attention, as time progresses the likelihood of developing DR increases. 20–30% of patients with Diabetic Retinopathy are at risk of going blind, with an average age range of 20–65.
With instant photographic analysis, testing and diagnosis can be conducted in one session
Capture an image and press analyze to view the results.
Install VeriSee on a computer with an ophthalmoscope connection and select a folder location for fundus image exports. Each time a fundus image is added to the folder, the image is automatically uploaded to VeriSee for quality verification. After image quality has been verified by the user, the image can be analyzed.
Batch analysis mode can be used to efficiently handle a large numbers of cases
Up to 1000 fundus images can be uploaded to VeriSee at once. Analysis files are saved in CSV format for convenient connection to hospital systems and for use in relevant research.
Exporting the fundus image and analysis report helps ensure smoother doctor-patient communication
Following analysis, reports can be edited and exported in PDF format.
VeriSee DR AI technology
After each image is uploaded
3 seconds
*
Assess whether there is a risk of diabetic retinopathy and need referral.
The clinical trial results reached
95%
Sensitivity
90%
Specificity
2018 12th Asia-Pacific Vitreo-retina Society (APVRS) Congress,
and 2019 Asia-Pacific Academy of Ophthalmology(APAO) Annual Congress
Journal of the Formosan Medical Association (2020). Application of deep learning image
assessment software VeriSee for diabetic retinopathy screening. (IF 2.844)
https://www.sciencedirect.com/science/article/pii/S0929664620301182
ClinicalTrials.gov